Abstract
Purpose :
To evaluate the efficacy of adjuvant topical dorzolamide-timolol in neovascular age-related macular degeneration (AMD) patients unresponsive to anti-vascular endothelial growth factor (VEGF).
Methods :
This retrospective, interventional study included 15 neovascular AMD patients unresponsive to anti-VEGF. Patients were instructed to use topical dorzolamide-timolol twice daily in the eye with neovascular AMD, and an anti-VEGF therapy was performed at each visit with the same fixed interval and the same agent as before the addition of dorzolamide-timolol. Central macular thickness, the maximal subretinal fluid height, and the maximal pigment epithelial detachment height were measured at baseline and every visit.
Results :
The mean central macular thickness decreased from 383.47μm at baseline to 298.27μm at final visit (p=0.041). The mean maximal subretinal fluid height decreased from 105.00μm at baseline to 58.27μm at final visit (p=0.021). Complete resolution of subretinal fluid was observed in 3 of 11 eyes with subretinal fluid type. There was no significant change in the maximal pigment epithelial detachment height and visual acuity. The mean intraocular pressure decreased significantly from 14.87mmHg at baseline to 12.33mmHg at final visit (p=0.005).
Conclusions :
An adjuvant use of topical dorzolamide-timolol was effective in neovascular AMD patients with persistent exudation despite anti-VEGF therapy with fixed intervals.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.